282: Lilly’s obesity drug, the power of radiation, & a biotech implosion
The Readout Loud
00:00
Introduction
The hosts discuss the scientific background of radio pharmaceuticals, Eli Lilly's new obesity treatment, a biotech blowup, and shareholder activism. They also touch on the future of genome sequencing and genetic association signals in an ad from Regeneron Genetics Center.
Transcript
Play full episode
